THE MYSTERY
OF ASTRAZENECA
Embedded Files
a cura di: Calabrese Claudia, Picciuto Paola, Salcuni Ludovica, Terenzi Matteo e Vignali Lucia
alunni della classe 3^B
THE DIFFERENT VACCINES: THE MYSTERY OF ASTRAZENECA
On 30th December 2020, in Italy and other European countries, began the vaccination campaign against Covid-19. In the final period of 2020 there was a small symbolic advance, with 9,750 doses, since the actual operation started in January. The first on the list were doctors, nurses, staff and guests of the Rsa, the health residences for the elderly.
THE MOST DISCUSSED
It contains a virus harmless to humans (modified Chimpanzé adenovirus,It has been modified to look more like coronavirus; although it can't cause illness.) which contains the DNA needed to produce the Spike protein. The cells infected by the virus produce the Spike protein, which stimulates the production of antibodies by the immune system.
AstraZeneca’s Covid-19 vaccine is facing a crisis of confidence, with one European country after another, as if seized by a fit of panic, temporarily suspending its use over concerns about reports of blood clots in people who received it.
Many states have stopped the vaccination campaign to assess the real risks posed by Astrazeneca.
Experts and Europe’s regulatory body insist that the vaccine’s benefit — preventing Covid-19 and helping to stop the pandemic — outweighs its risks. They note that the number of people to report the side effect is relatively small, and no causal link has been established.
But experts are also now worried that the decisions by multiple countries to suspend the vaccine’s use could make it harder to convince people to receive it should the concerns turn out, as they expect, to be a false alarm
In one year occur in the general population aged between 35 and 70 years about 80 DVT (Deep Vein Thrombosis) cases per 100,000 people Leading to an expected number of cases of 6-8 DVT cases per month per 100,000 people.
VAXZEVRIA??
AstraZeneca's vaccine changed its name to "Vaxzevria". The name change was approved by the EMA following a request from the Anglo-Swedish pharmaceutical group. AstraZeneca "has registered the name", first generically baptized: "Vaccine Covid-19 AstraZeneca" and without a real name. "Naming a new drug is customary and is a process that takes place separately from the regulatory approvation.
Page updated
Google Sites
Report abuse